Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Total Current Liabilities (2020 - 2023)

Cullinan Therapeutics has reported Total Current Liabilities over the past 4 years, most recently at $23.4 million for Q3 2023.

  • Quarterly results put Total Current Liabilities at $23.4 million for Q3 2023, down 13.55% from a year ago — trailing twelve months through Sep 2023 was $23.4 million (down 13.55% YoY), and the annual figure for FY2022 was $22.5 million, up 91.54%.
  • Total Current Liabilities for Q3 2023 was $23.4 million at Cullinan Therapeutics, up from $19.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CGEM hit a ceiling of $62.0 million in Q2 2022 and a floor of $5.7 million in Q2 2021.
  • Median Total Current Liabilities over the past 4 years was $18.5 million (2022), compared with a mean of $20.6 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 980.18% in 2022 and later tumbled 68.28% in 2023.
  • Cullinan Therapeutics' Total Current Liabilities stood at $14.3 million in 2020, then fell by 17.97% to $11.7 million in 2021, then soared by 91.54% to $22.5 million in 2022, then increased by 4.2% to $23.4 million in 2023.
  • The last three reported values for Total Current Liabilities were $23.4 million (Q3 2023), $19.7 million (Q2 2023), and $26.2 million (Q1 2023) per Business Quant data.